Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

To be Wild or Mutant: Role of Isocitrate Dehydrogenase 1 (IDH1) and 2-Hydroxy Glutarate (2-HG) in Gliomagenesis and Treatment Outcome in Glioma.

Bhavya B, Anand CR, Madhusoodanan UK, Rajalakshmi P, Krishnakumar K, Easwer HV, Deepti AN, Gopala S.

Cell Mol Neurobiol. 2019 Sep 4. doi: 10.1007/s10571-019-00730-3. [Epub ahead of print] Review.

PMID:
31485826
2.

Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.

Han CH, Batchelor TT.

Chin Clin Oncol. 2017 Jun;6(3):33. doi: 10.21037/cco.2017.06.11.

3.

Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.

Ma T, Zou F, Pusch S, Xu Y, von Deimling A, Zha X.

J Med Chem. 2018 Oct 25;61(20):8981-9003. doi: 10.1021/acs.jmedchem.8b00159. Epub 2018 Jun 18. Review.

PMID:
29847930
4.

IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma.

Zhang C, Moore LM, Li X, Yung WK, Zhang W.

Neuro Oncol. 2013 Sep;15(9):1114-26. doi: 10.1093/neuonc/not087. Epub 2013 Jul 21. Review.

5.

IDH mutations in cancer and progress toward development of targeted therapeutics.

Dang L, Yen K, Attar EC.

Ann Oncol. 2016 Apr;27(4):599-608. doi: 10.1093/annonc/mdw013. Review.

PMID:
27005468
6.

Elevation of Urinary 2-Hydroxyglutarate in IDH-Mutant Glioma.

Fathi AT, Nahed BV, Wander SA, Iafrate AJ, Borger DR, Hu R, Thabet A, Cahill DP, Perry AM, Joseph CP, Muzikansky A, Chi AS.

Oncologist. 2016 Feb;21(2):214-9. doi: 10.1634/theoncologist.2015-0342. Epub 2016 Feb 1.

7.

Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis.

Ohba S, Hirose Y.

Neurol Med Chir (Tokyo). 2016;56(4):170-9. doi: 10.2176/nmc.ra.2015-0322. Epub 2016 Mar 10. Review.

8.

Rapid Conversion of Mutant IDH1 from Driver to Passenger in a Model of Human Gliomagenesis.

Johannessen TA, Mukherjee J, Viswanath P, Ohba S, Ronen SM, Bjerkvig R, Pieper RO.

Mol Cancer Res. 2016 Oct;14(10):976-983. Epub 2016 Jul 18.

9.

Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.

Miller JJ, Shih HA, Andronesi OC, Cahill DP.

Cancer. 2017 Dec 1;123(23):4535-4546. doi: 10.1002/cncr.31039. Epub 2017 Oct 5. Review.

10.

Isocitrate dehydrogenase mutations in gliomas.

Waitkus MS, Diplas BH, Yan H.

Neuro Oncol. 2016 Jan;18(1):16-26. doi: 10.1093/neuonc/nov136. Epub 2015 Jul 16. Review.

11.

Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.

Ma R, Yun CH.

Biochem Biophys Res Commun. 2018 Sep 18;503(4):2912-2917. doi: 10.1016/j.bbrc.2018.08.068. Epub 2018 Aug 18.

PMID:
30131249
12.

Targeting isocitrate dehydrogenase (IDH) in cancer.

Fujii T, Khawaja MR, DiNardo CD, Atkins JT, Janku F.

Discov Med. 2016 May;21(117):373-80. Review.

13.

Biological Role and Therapeutic Potential of IDH Mutations in Cancer.

Waitkus MS, Diplas BH, Yan H.

Cancer Cell. 2018 Aug 13;34(2):186-195. doi: 10.1016/j.ccell.2018.04.011. Epub 2018 May 24. Review.

14.

Consequences of IDH1/2 Mutations in Gliomas and an Assessment of Inhibitors Targeting Mutated IDH Proteins.

Kaminska B, Czapski B, Guzik R, Król SK, Gielniewski B.

Molecules. 2019 Mar 9;24(5). pii: E968. doi: 10.3390/molecules24050968. Review.

15.

The effects of 2-hydroxyglutarate on the tumorigenesis of gliomas.

Reiter-Brennan C, Semmler L, Klein A.

Contemp Oncol (Pozn). 2018;22(4):215-222. doi: 10.5114/wo.2018.82642. Epub 2018 Dec 31. Review.

16.

An in vivo patient-derived model of endogenous IDH1-mutant glioma.

Luchman HA, Stechishin OD, Dang NH, Blough MD, Chesnelong C, Kelly JJ, Nguyen SA, Chan JA, Weljie AM, Cairncross JG, Weiss S.

Neuro Oncol. 2012 Feb;14(2):184-91. doi: 10.1093/neuonc/nor207. Epub 2011 Dec 13.

17.

ML309: A potent inhibitor of R132H mutant IDH1 capable of reducing 2-hydroxyglutarate production in U87 MG glioblastoma cells.

Davis M, Pragani R, Popovici-Muller J, Gross S, Thorne N, Salituro F, Fantin V, Straley K, Su M, Dang L, Simeonov A, Shen M, Boxer MB.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2012 Apr 16 [updated 2013 May 8].

18.

Mutant IDH1 and thrombosis in gliomas.

Unruh D, Schwarze SR, Khoury L, Thomas C, Wu M, Chen L, Chen R, Liu Y, Schwartz MA, Amidei C, Kumthekar P, Benjamin CG, Song K, Dawson C, Rispoli JM, Fatterpekar G, Golfinos JG, Kondziolka D, Karajannis M, Pacione D, Zagzag D, McIntyre T, Snuderl M, Horbinski C.

Acta Neuropathol. 2016 Dec;132(6):917-930. Epub 2016 Sep 23.

19.

Isocitrate dehydrogenase (IDH) mutations promote a reversible ZEB1/microRNA (miR)-200-dependent epithelial-mesenchymal transition (EMT).

Grassian AR, Lin F, Barrett R, Liu Y, Jiang W, Korpal M, Astley H, Gitterman D, Henley T, Howes R, Levell J, Korn JM, Pagliarini R.

J Biol Chem. 2012 Dec 7;287(50):42180-94. doi: 10.1074/jbc.M112.417832. Epub 2012 Oct 4.

20.

Lack of evidence for substrate channeling or flux between wildtype and mutant isocitrate dehydrogenase to produce the oncometabolite 2-hydroxyglutarate.

Dexter JP, Ward PS, Dasgupta T, Hosios AM, Gunawardena J, Vander Heiden MG.

J Biol Chem. 2018 Dec 28;293(52):20051-20061. doi: 10.1074/jbc.RA118.004278. Epub 2018 Oct 31.

PMID:
30381394

Supplemental Content

Support Center